Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Central 2, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan.
J Biol Chem. 2012 Jun 8;287(24):20313-20. doi: 10.1074/jbc.M112.351965. Epub 2012 Apr 5.
6-sulfo-galactose (6S-Gal) is a prevalent motif observed in highly sulfated keratan sulfate, which is closely associated with the glioblastoma malignancy while acting as a critical determinant for endogenous lectins. However, facile detection of this unique glycoepitope is greatly hampered because of a lack of appropriate probes. We have previously reported tailoring an α2-6-linked sialic acid-binding lectin from a ricin-B chain-like galactose-binding protein, EW29Ch, by a reinforced ribosome display system following an error-prone PCR. In this study, we challenged the creation of novel lectins to recognize 6S-Gal-terminated glycans by incorporating a high-throughput screening system with a glycoconjugate microarray. After two rounds of selection procedures, 20 mutants were obtained and 12 were then successfully expressed in Escherichia coli, 8 of which showed a significant affinity for 6'-Sulfo-LN (6-O-sulfo-Galβ1-4GlcNAc), which the parental EW29Ch lacked. Analysis of two representative mutants by frontal affinity chromatography revealed a substantial affinity (K(d) ∼3 μm) for a 6S-Gal-terminated glycan. On the basis of the observation that all eight mutants have a common mutation at Glu-20 to Lys, site-directed mutagenesis experiments were performed focusing on this aspect. The results clearly indicated that the E20K mutation is necessary and sufficient to acquire the specificity for 6S-Gal. We also confirmed a difference in binding between E20K and EW29Ch to CHO cells, in which enzymes to catalyze the synthesis of 6S-Gal were overexpressed. The results clearly demonstrate that these mutants have potential to distinguish between cells containing different amounts of 6S-Gal-terminated glycans. This new technology will be used to provide novel tools essential for sulfoglycomics.
6- 磺酸半乳糖(6S-Gal)是高度硫酸化的角蛋白硫酸中常见的结构基序,与神经胶质瘤的恶性程度密切相关,同时也是内源性凝集素的关键决定因素。然而,由于缺乏合适的探针,这种独特的糖基表位的检测非常困难。我们之前曾报道过,通过易错 PCR 后使用强化核糖体展示系统,对 ricin-B 链样半乳糖结合蛋白 EW29Ch 进行修饰,得到一种可以结合 α2-6 连接的唾液酸的凝集素。在这项研究中,我们通过结合糖缀合物微阵列的高通量筛选系统,挑战创造能够识别 6S-Gal 末端聚糖的新型凝集素。经过两轮选择程序,获得了 20 个突变体,其中 12 个突变体在大肠杆菌中成功表达,其中 8 个对 6'-Sulfo-LN(6-O-磺酸-Galβ1-4GlcNAc)具有显著亲和力,而亲本 EW29Ch 则没有。通过前沿亲和层析分析两个代表性突变体表明,它们对 6S-Gal 末端聚糖具有相当大的亲和力(K(d)∼3 μm)。基于观察到所有 8 个突变体在Glu-20 到 Lys 都有一个共同的突变,我们进行了定点突变实验,重点关注这一方面。结果清楚地表明,E20K 突变是获得 6S-Gal 特异性所必需和充分的。我们还证实了 E20K 和 EW29Ch 与过表达催化 6S-Gal 合成的酶的 CHO 细胞之间的结合差异。结果清楚地表明,这些突变体有可能区分含有不同量 6S-Gal 末端聚糖的细胞。这项新技术将用于提供对糖基硫化组学至关重要的新工具。